贝塔抑制剂使用与前列腺癌死亡率之间的关联:小型系统性审查和元分析
Alessandro Uleri1,2, Michael Baboudjian3, Alessandro Tedde4
1Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
The Prostate
|September 15, 2023
概括
贝塔抑制剂的使用不会影响前列腺癌 (PCa) 死亡率或整体存活率. 这项大型元分析为临床医生和患者提供了关于在PCa护理中使用β-阻断剂的关键数据.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 流行病学 流行病学
背景情况:
- 临床前数据表明交感神经系统参与转移,这意味着β-阻断剂的潜在抗瘤作用.
- 关于使用β-阻断剂和前列腺癌 (PCa) 死亡率存在长达十年的争议.
- 这项研究系统地审查了β阻断剂使用与PCa生存结果之间的关联.
结论:
- 使用β阻塞剂与前列腺癌死亡率或整体存活率无关.
- 这一全面的元分析为临床实践和患者咨询提供了宝贵的见解.
- 这些发现为正在进行的关于瘤学中的β-阻断剂的讨论提供了重要的数据.
相关概念视频
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
886
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
886
Antihypertensive Drugs: Types of β-Blockers
732
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
732
Heart Failure Drugs: β-Blockers
363
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
363
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
657
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
657
Antihypertensive Drugs: Action of β1 Blockers
476
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
476
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
887
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
887


